Repurposing selective serotonin reuptake inhibitors for severity of COVID-19 : A population-based study
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved..
The World Health Organization has proposed that a search be made for alternatives to vaccines for the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought to assess: the impact of previous treatment with SSRI antidepressants on the severity of COVID-19 (risk of hospitalisation, admission to an intensive care unit [ICU], and mortality), its influence on susceptibility to SARS-CoV-2 and progression to severe COVID-19. We conducted a population-based multiple case-control study in a region in the north-west of Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) and 95%CIs were calculated using multilevel logistic regression. We collected data from a total of 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised cases PCR+ and 56,785 controls (without PCR+). Citalopram displayed a statistically significant decrease in the risk of hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) and progression to severe COVID-19 (aOR=0.64; 95% CI 0.43-0.96, p = 0.032). Paroxetine was associated with a statistically significant decrease in risk of mortality (aOR=0.34; 95% CI 0.12 - 0.94, p = 0.039). No class effect was observed for SSRIs overall, nor was any other effect found for the remaining SSRIs. The results of this large-scale, real-world data study indicate that, citalopram, could be a candidate drug for being repurposed as preventive treatment aimed at reducing COVID-19 patients' risk of progressing to severe stages of the disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 71(2023) vom: 01. Juni, Seite 96-108 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Visos-Varela, Irene [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 31.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euroneuro.2023.03.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35598167X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35598167X | ||
| 003 | DE-627 | ||
| 005 | 20231226065507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2023.03.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM35598167X | ||
| 035 | |a (NLM)37094487 | ||
| 035 | |a (PII)S0924-977X(23)00063-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Visos-Varela, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing selective serotonin reuptake inhibitors for severity of COVID-19 |b A population-based study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 31.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a The World Health Organization has proposed that a search be made for alternatives to vaccines for the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought to assess: the impact of previous treatment with SSRI antidepressants on the severity of COVID-19 (risk of hospitalisation, admission to an intensive care unit [ICU], and mortality), its influence on susceptibility to SARS-CoV-2 and progression to severe COVID-19. We conducted a population-based multiple case-control study in a region in the north-west of Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) and 95%CIs were calculated using multilevel logistic regression. We collected data from a total of 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised cases PCR+ and 56,785 controls (without PCR+). Citalopram displayed a statistically significant decrease in the risk of hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) and progression to severe COVID-19 (aOR=0.64; 95% CI 0.43-0.96, p = 0.032). Paroxetine was associated with a statistically significant decrease in risk of mortality (aOR=0.34; 95% CI 0.12 - 0.94, p = 0.039). No class effect was observed for SSRIs overall, nor was any other effect found for the remaining SSRIs. The results of this large-scale, real-world data study indicate that, citalopram, could be a candidate drug for being repurposed as preventive treatment aimed at reducing COVID-19 patients' risk of progressing to severe stages of the disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antidepressants | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Citalopram | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Hospitalisation | |
| 650 | 4 | |a Serotonin and noradrenaline reuptake inhibitors | |
| 650 | 7 | |a Selective Serotonin Reuptake Inhibitors |2 NLM | |
| 650 | 7 | |a Citalopram |2 NLM | |
| 650 | 7 | |a 0DHU5B8D6V |2 NLM | |
| 700 | 1 | |a Zapata-Cachafeiro, Maruxa |e verfasserin |4 aut | |
| 700 | 1 | |a Piñeiro-Lamas, María |e verfasserin |4 aut | |
| 700 | 1 | |a Carracedo-Martínez, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Saez, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Herdeiro, María Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiras, Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Salgado-Barreira, Ángel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 71(2023) vom: 01. Juni, Seite 96-108 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2023 |g day:01 |g month:06 |g pages:96-108 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2023.03.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2023 |b 01 |c 06 |h 96-108 | ||